In addition, the Inflation Reduction Act of 2022 (“IRA”) contains provisions intended to lower beneficiary drug spending. Beginning in 2023, the IRA enables Medicare to negotiate prescription drug prices with manufacturers of certain high-cost drugs for the first time. Each year, CMS will select and negotiate a preset number of high-spend drugs and biologics that are covered under Medicare Part B and Part D that do not have generic or biosimilar competition. In January 2025, CMS announced a list of fifteen additional Medicare Part D drugs that will be subject to price negotiations. To date, none of our products have been selected to be subject to price negotiations.
All entries for: Hematology
March 12, 2026
Corvus Pharmaceuticals, Inc.
Neutral Outlook
South San Francisco, CA
51-200 employees
For that and other reasons, it is currently unclear how the IRA will be effectuated.
Disease Area: Dermatology, Hematology, Immune Diseases, Oncology
Drug Type: Biologic, Small Molecule
March 12, 2026
Adicet Bio, Inc.
Neutral Outlook
Boston, MA
51-200 employees
Although the effects of the IRA on our business and the healthcare industry in general is not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
Disease Area: Hematology, Immune Diseases, Oncology
Drug Type: Biologic
March 12, 2026
Precision Biosciences Inc
Neutral Outlook
Durham, NC
51-200 employees
While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Antiviral, Hematology, Immune Diseases, Infectious Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic
March 10, 2026
ADC Therapeutics SA-Switzerland
Neutral Outlook
Switzerland
51-200 employees
Thus, while it is unclear how some provisions of the IRA will be implemented, we are liable for Part B inflation rebates for ZYNLONTA under the IRA, which has and will continue to negatively impact our gross-to-net adjustment for ZYNLONTA sales.
Disease Area: Hematology, Oncology
Drug Type: Biologic
March 9, 2026
Macrogenics Inc
Neutral Outlook
Rockville, MD
201-500 employees
For example, on August 16, 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law, which among other things, (i) extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025, (ii) authorizes HHS to negotiate the price of certain high-expenditure, single-source drugs covered under Medicare that have been on the market for at least 7 years, and (iii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation.
Disease Area: Endocrinology, Hematology, Oncology
Drug Type: Biologic